Lv45
506 积分 2026-03-09 加入
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial
14天前
已完结
Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis
16天前
已完结
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
16天前
已完结
Physical Activity and Excess Body Weight and Adiposity for Adults. American College of Sports Medicine Consensus Statement
18天前
已完结
Why does GLP ‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP ‐1 agonist alone in obese adults without type 2 diabetes?
22天前
已完结
Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial
1个月前
已关闭
MASLD, MASH, and the CKM Spectrum
1个月前
已完结
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association
1个月前
已完结
Chronic Inflammation as an Overlooked Link between Cardiovascular and Kidney Disease
1个月前
已完结
763-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study
1个月前
已关闭
皖公网安备34019202002308
